BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1237 related articles for article (PubMed ID: 10985481)

  • 41. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
    Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement.
    Anselmo AP; Bove M; Cartoni C; Damico C; Maurizi Enrici R; Falchetto Osti M; Biagini C
    Haematologica; 1992; 77(2):177-9. PubMed ID: 1383107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
    Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of radiotherapy in the treatment of stage I-II Hodgkin's disease in children].
    Kanaev SV; Kolygin BA; Malinin AP; Chikrizov SI
    Med Radiol (Mosk); 1986 Jul; 31(7):14-8. PubMed ID: 3755492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Primary treatment of advanced Hodgkin's disease].
    Illés A; Udvardy M; Molnár Z
    Orv Hetil; 2005 Jan; 146(5):195-202. PubMed ID: 15773586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy.
    Bonadonna G; Valagussa P; Santoro A
    Cancer Surv; 1985; 4(2):439-58. PubMed ID: 2430700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of Hodgkin's disease. National Protocol of Antineoplastic Drugs: preliminary report].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Jan; 119(1):11-21. PubMed ID: 1726700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The chemotherapeutic treatment of advanced Hodgkin's disease].
    Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
    Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of Hodgkin's disease in children with chemotherapy and low-dose radiation].
    Leverger G; Oberlin O; Schaison G; Lemerle J
    Nouv Rev Fr Hematol (1978); 1987; 29(1):83-5. PubMed ID: 2438648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The role of radiotherapy in the treatment of Stage IIIA Hodgkin's disease in children].
    Kanaev SV; Kolygin BA; Malinin AP; Chikrizov SI
    Vopr Onkol; 1986; 32(9):53-6. PubMed ID: 3765524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.